Prevents organ rejection. ANDA 216390, held by Onesource Specialty. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 216390 (Mycophenolate Mofetil Hydrochloride), held by Onesource Specialty, was first approved by FDA on Dec 23, 2022, with 3 approved supplements and 0 published complete response letters.
Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 5REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 3REMS | Approved | None posted |
| Jun 22, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 23, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters